Paper Details
- Home
- Paper Details
Conversion From Intravenous In-Hospital Belatacept Injection to Subcutaneous Abatacept Injection in Kidney Transplant Recipients During the First COVID-19 Stay-at-Home Order in France.
Author: AmroucheLucile, AnglicheauDany, BertrandDominique, BrunelMélanie, GuerrotDominique, LaurentCharlotte, LebourgLudivine, LegendreChristophe, LemoineMathilde, Sberro-SoussanRebecca, ScemlaAnne
Original Abstract of the Article :
The first COVID-19 stay-at-home order came into effect in France on 17 March 2020. Immunocompromised patients were asked to isolate themselves, and outpatient clinic visits were dramatically reduced. In order to avoid visits to the hospital by belatacept-treated kidney transplant recipients (KTRs) d...See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10405172/
データ提供：米国国立医学図書館（NLM）
Adapting Immunosuppressive Therapy During a Pandemic: A Case Study in Kidney Transplant Recipients
The COVID-19 pandemic presented significant challenges for healthcare systems worldwide, including the management of immunosuppressed patients, such as kidney transplant recipients. This research explores a practical approach to adapting immunosuppressive therapy during the early stages of the pandemic, focusing on a cohort of kidney transplant recipients treated with belatacept. The study investigates the feasibility and safety of switching these patients to subcutaneous abatacept, a different immunosuppressant, to minimize their need for hospital visits during the pandemic's initial stay-at-home orders.
Conversion to Subcutaneous Abatacept: A Successful Approach for Kidney Transplant Recipients
The study demonstrates the successful conversion of kidney transplant recipients from intravenous belatacept to subcutaneous abatacept. The switch appeared to be feasible and safe, with a stable mean eGFR and a low incidence of serious adverse events.
Navigating Immunosuppression During a Pandemic: Balancing Infection Risk and Treatment Efficacy
This research highlights the complexities of managing immunosuppressed patients during a pandemic. The study's successful conversion to subcutaneous abatacept demonstrates a potential approach to reduce hospital visits while maintaining treatment efficacy. However, it's essential to weigh the potential risks and benefits of adjusting immunosuppressive therapy carefully, considering individual patient factors and the evolving nature of the pandemic.
Dr.Camel's Conclusion
This research provides a compelling case study of adapting immunosuppressive therapy in kidney transplant recipients during the early stages of the COVID-19 pandemic. The successful conversion to subcutaneous abatacept demonstrates a potential approach to minimizing hospital visits while maintaining treatment efficacy. This research highlights the importance of flexibility and adaptability in managing immunosuppressed patients during public health emergencies.
Date :
- Date Completed 2023-08-10
- Date Revised 2023-08-24
Further Info :
Related Literature
English
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.